Myelodysplastic Syndrome
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-01-30Clinical Trial Update: Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia [Phase 1]
Phase I trial evaluating AZD1775 in combination with belinostat for relapsed or refractory myeloid malignancies or untreated acute myeloid l…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH [Phase 1]
Phase 1 study of HMPL-306 in advanced hematologic cancers with IDH mutation has been terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed [Phase 1, Phase 2]
Phase 1/2 study of guadecitabine plus atezolizumab in adults with advanced myelodysplastic syndrome or chronic myelomonocytic leukemia that …
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms [Phase 1]
Phase 1 safety, tolerability and preliminary efficacy study of NC525 in adults with advanced myeloid neoplasms has been terminated and resul…
-
CLINICAL_TRIALS trial_result · 2026-01-23Clinical Trial Update: Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML [Phase 1]
Phase 1 dose-escalation trial evaluating LP-108 as monotherapy and in combination with azacitidine in adults with relapsed or refractory mye…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-16Clinical Trial Update: Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies
The Orca-T Expanded Access Program study for patients with advanced hematologic malignancies has a status update. The study is temporarily n…
-
CLINICAL_TRIALS trial_result · 2026-01-16Clinical Trial Update: Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation [Phase 1]
A Phase 1 trial evaluating Velcade (bortezomib) and lenalidomide in patients with relapsed myelodysplastic syndrome or acute myeloid leukemi…
-
CLINICAL_TRIALS trial_result · 2026-01-16Clinical Trial Update: CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML or HR-MDS [Phase 1]
Phase 1 clinical trial of CD64 CAR T cell therapy for adults with relapsed/refractory AML or high-risk MDS. The trial status is not yet recr…
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML
This clinical trial update covers the efficacy and safety of combining hypomethylating agents with venetoclax versus hypomethylating agents …
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN [Phase 1]
This Phase 1 trial update reports adding venetoclax to fludarabine and busulfan conditioning before transplant and to maintenance therapy fo…
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes [Phase 2]
Phase 2 trial evaluating adding pomalidomide to the standard liposomal daunorubicin/cytarabine chemotherapy in newly diagnosed acute myeloid…
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: Off-the-shelf NK Cells + SCT for Myeloid Malignancies [Phase 2]
Phase 2 trial evaluating off-the-shelf natural killer (NK) cells in combination with stem cell transplantation for myeloid malignancies has …
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating cytokine-treated veto cells as an adoptive therapy after stem cell transplantation for various hematolog…
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers [Phase 2]
Phase 2 trial evaluating Dexrazoxane hydrochloride to prevent heart-related side effects of chemotherapy in people with blood cancers; the s…
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating guadecitabine in combination with donor lymphocyte infusion for acute myeloid leukemia, chronic myelomonoc…
-
CLINICAL_TRIALS trial_result · 2025-11-03Clinical Trial Update: Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 [Phase 1, Phase 2]
This clinical trial update reports a Phase 1/2 study of the combination omacetaxine mepesuccinate and venetoclax in relapsed or refractory a…
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating reduced-intensity conditioning before allogeneic donor stem cell transplantation in patients with high-risk hematol…
-
CLINICAL_TRIALS trial_result · 2025-10-21Clinical Trial Update: Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) [Phase 1]
Phase 1 clinical trial evaluating the administration of donor-derived multi TAA-specific T cells (ADSPAM) for acute myeloid leukemia or myel…
-
CLINICAL_TRIALS trial_result · 2025-09-26Clinical Trial Update: Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies [Phase 3]
A Phase 3 randomized trial evaluating Orca-T in allogeneic stem cell transplantation for hematologic malignancies; results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-09-08Clinical Trial Update: PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK) [Phase 2]
Phase 2 trial of PF-05212384 (PKI-587) for therapy-related AML/MDS and de novo/relapsed or refractory AML was terminated. The update indicat…
-
CLINICAL_TRIALS trial_result · 2025-08-07Clinical Trial Update: Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) [Phase 2]
Phase II trial comparing decitabine versus azacitidine in myelodysplastic syndrome has completed; results were posted on 2025-08-07.
-
CLINICAL_TRIALS trial_result · 2025-07-31Clinical Trial Update: STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS [Phase 2]
Phase 2 STIMULUS MDS-US trial evaluating Sabatolimab added to hypomethylating agents in higher-risk myelodysplastic syndrome has been termin…
-
CLINICAL_TRIALS trial_result · 2025-07-11Clinical Trial Update: CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene [Phase 1]
Phase 1 clinical trial of CASPALLO allodepleted T cells engineered with an inducible caspase-9 suicide gene; the study is currently active b…
-
CLINICAL_TRIALS trial_result · 2025-07-04Clinical Trial Update: UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep [Phase 2]
Phase 2 clinical trial evaluating non-myeloablative preparative regimens followed by umbilical cord blood transplantation for various hemato…
-
CLINICAL_TRIALS trial_result · 2025-06-26Clinical Trial Update: Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation [Phase 1, Phase 2]
Open-label Phase 1/2 trial of FT-2102 in IDH1-mutant acute myeloid leukemia and myelodysplastic syndrome, evaluating FT-2102 with or without…